Johnson & Johnson (NYSE:JNJ) Shares Sold by Goldstream Capital Management Ltd

Goldstream Capital Management Ltd decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 56.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,582 shares of the company's stock after selling 3,289 shares during the period. Johnson & Johnson accounts for about 0.1% of Goldstream Capital Management Ltd's portfolio, making the stock its 27th largest position. Goldstream Capital Management Ltd's holdings in Johnson & Johnson were worth $373,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of JNJ. Oregon Pacific Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $949,000. Horan Securities Inc. boosted its stake in Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after acquiring an additional 90 shares in the last quarter. Strategic Financial Concepts LLC grew its holdings in Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock worth $501,000 after purchasing an additional 1,271 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth $69,859,000. Finally, KPP Advisory Services LLC boosted its position in shares of Johnson & Johnson by 4.7% in the 4th quarter. KPP Advisory Services LLC now owns 11,492 shares of the company's stock worth $1,662,000 after purchasing an additional 515 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 1.5 %

NYSE:JNJ traded down $2.40 on Wednesday, reaching $155.35. The company's stock had a trading volume of 9,097,317 shares, compared to its average volume of 7,923,271. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The stock has a 50 day moving average price of $159.54 and a 200 day moving average price of $154.95. The firm has a market cap of $374.36 billion, a price-to-earnings ratio of 23.36, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.35%. Johnson & Johnson's dividend payout ratio is 57.84%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on JNJ. Bank of America lowered their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $171.82.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.